Yes, it does sound like a lot more patience is going to be required. I am grateful for Dr. seymour's responses, although I am somewhat disappointed in the answers. When he states, "...a minimal amount of tweaking will be necessary..." I take away that since the initial results there has not been any new testing, at least that is what the word "will" says to me--I had hoped that the tweaking had already been taking place. Also, to get a priority review voucher you must obtain FDA approval for a drug that has gone through normal channels (if my memory is correct--we went through all this once before) so even if the Denguecide is the first in line, we must still be a couple of years or more away from possible approval? It would seem we are still months away from the preIND meeting, then months away from compliance with the FDA requirements, then Phases I and II, and then Phase III? And then still more months for FDA panels and then, if all went well, more months before FDA approval. I guess there is no getting around all of this. I am now more skeptical that anything new will be revealed in the Puerto Rico conference. I am hopeful, but skeptical. Sure, as these issues on the timeline are accomplished, including the acquisition of the manufacturing facility, the share price will hopefully come along for the ride. But I expect many more peaks and troughs. Just have to ride it out with an eye on the long-term prize. I am definitely of the opinion that Hawaii is more than a couple of years away.
Lee
News 
Market Data 
Discover 
AI
